The potential association of herpes zoster with giant cell arteritis (GCA) has been a debated topic and certainly has gotten some attention at ACR 2016 this year.

The annual ACR meeting began last night with a number of famed rheumatologists being inducted as ACR Masters.

The opening day plenary session at ACR 2016 this morning featured John H.

Treatment of giant cell arteritis with tocilizumab is a hot topic at this year’s ACR meeting and, while GiACTA data was promising, a Swiss study reported less-favorable results at the poster session this morning (

Rheumatologists have been challenged to treat hepatitis C virus (HCV)-induced rheumatic disease since discovery of the virus in 1989.

Dr. Jack Cush reviews highlights from the journals and news this week on RheumNow.com.

Dr. Jack Cush reviews highlights from the past week on RheumNow.com, including IBD/TNFi and cancer risk, fracture nonunion, PMR worse in women, not treating asymptomatic hyperuricemia, and shingles followed by stroke.

Dr. Jack Cush reviews highlights from this week in RheumNow:

From tofacitinib developmental trials in RA and psoriasis and adherence to T2T in early RA to a rheumatology pearl about dapsone and much more, here are the highlights of what you may have missed on RheumNow.com this week.

The issue of lower intestinal tract perforation (LIP) is no novelty to rheumatologists since the RA treatment paradigm shifted from use of NSAIDs (the most common cause of upper GI tract perforations) to steroids and non-steroidal DMARDs.

Dr. Jack Cush reviews highlights from this week's rheumatology news on RheumNow.com.

A EULAR task force has updated its 2009 recommendations for the management of anti-neutrophil cytoplasmic antibody associated vasculitis. 

The GiACTA study has published its top line results demonstrating the efficacy of adding tocilizumab (TCZ) to steroid-tapered therapy in patients with giant cell arteritis (GCA). 

The damaging potential of many inflammatory disorders is magnified by well-known associated comorbid conditions. This is particularly true in lupus, rheumatoid arthritis and psoriatic disease.

Polymyalgia rheumatica (PMR) should be easy and responsive, but it can be a challenge and requires long-term steroid therapy. Problems often begin when steroid–induced side effects take their toll on a patient, especially in elderly adults.

The widespread use of existing biologics has sometimes been associated with the paradoxical development of biologic-induced autoimmune phenomena, including vasculitis. A recent review of more than 200 vasculitis cases associated with biologic use has profiled the range of these unsual and rare events.

Highlights from this week on RheumNow.com

Lancet has reported the results of a randomized, double-blind, placebo-controlled trial of tocilizumab in patients with new-onset giant cell arteritis (GCA).

Overall survival and survival free of end-stage renal disease (ESRD) have both improved significantly over time in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), but the risk of relapse has not.

Patients with giant cell arteritis (GCA) had a higher rate of severe infections compared with the general population, a French study found.